** Shares of cancer testing services company NeoGenomics NEO.O fall ~15% to $12.2 in morning trade
** NEO posts Q4 revenue of $172 million, missing analysts' estimates of $173.2 million, according to data compiled by LSEG
** Company reports adj. Q4 profit of 4 cents/shr, compared to analysts' estimates of 3 cents/shr
** Company forecasts net loss of $85 million to $76 million for 2025
** NEO also forecasts 2025 revenue in the range of $735 million to $745 million
** Stock down 3.2% over the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。